Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from FibroBiologics, Inc. ( (FBLG) ).
FibroBiologics, Inc. announced a $25 million Standby Equity Purchase Agreement with YA II PN LTD., managed by Yorkville Advisors Global, LP, allowing the sale of its common stock over two years. This financing will support FibroBiologics in conducting its first-in-human trials for diabetic foot ulcers and IND-enabling studies for psoriasis, as well as further development of treatments for human longevity, multiple sclerosis, and cancer.
More about FibroBiologics, Inc.
Based in Houston, FibroBiologics is a clinical-stage biotechnology company focused on developing treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds over 160 patents and is advancing cell therapy research across multiple clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
YTD Price Performance: -92.27%
Average Trading Volume: 170,998
Technical Sentiment Consensus Rating: Strong Buy
For an in-depth examination of FBLG stock, go to TipRanks’ Stock Analysis page.
